Lysophosphatidylcholines inhibit human eosinophil activation and suppress eosinophil migration in vivo

Knuplez, Eva; Curcic, Sanja; Theiler, Anna; Bärnthaler, Thomas; Trakaki, Athina; Trieb, Markus; Holzer, Michael; Heinemann, Ákos; Zimmermann, R.; Sturm, Eva; Marsche, Gunther

doi:10.1016/j.bbalip.2020.158686

Cited by 26 publications

(38 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These changes cause increased osteoclast activity and decreased osteoblast activity ( Delgado et al, 2016 ; Hirschberg et al, 2020 ). In postmenopausal women, in addition to the above factors, there are also the decline in estrone, estradiol, and estriol, which accelerate the decline in osteoblast activity, reduce bone matrix formation, and increase bone resorption ( Fallah et al, 2013 ; Knuplez et al, 2020 ). Lysophosphatidylcholines (Lyso PC), also known as lysolecithin, is a class of phosphatidylcholine (PC) -derived compounds that are partially hydrolyzed by the removal of a FA group from PC.…”

Section: Discussionmentioning

confidence: 99%

High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways to Evaluating the Efficacy and Exploring Potential Mechanisms of Osthole Against Osteoporosis Based on UPLC/Q-TOF-MS Coupled With Multivariate Data Analysis

Zhou

Shen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Postmenopausal osteoporosis (PMOP) is the most common metabolic bone illness among the elderly especially in postmenopausal women resulting from a reduction in bone mineral density, but there is no effective drug at present. The study was aimed at evaluating efficacy of osthole against osteoporosis using high-throughput metabolomics method. The blood samples for illustrating the pathological mechanism of PMOP and exploring the efficacy of osthole treatment (ST) were collected to perform metabolites and metabolic profiles and pathways analysis using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) and pattern recognition methods. In addition, backbone weight, the bone density, and some vital biochemical indexes were also detected. A total of 28 metabolites were identified as biomarkers for ovariectomized-osteoporosis model, and ST could significantly regulate 19 of them including lysine, linoleic acid, 3-hydroxybutyric acid, prostaglandin F2a, taurocholic acid, LysoPC(15:0), l -carnitine, glucose, arginine, citric acid, corticosterone, ornithine, tryptophan, arachidonic acid, Cer(d18:0/18:0), glutamine, uric acid, 8-HETE, estriol, which mainly related with 13 metabolic pathways, such as linoleic acid metabolism, starch, and sucrose metabolism, arachidonic acid metabolism, alanine, aspartate and glutamate metabolism, arginine and proline metabolism, citrate cycle (TCA cycle), and arginine biosynthesis. The ovariectomized model (OVX) rats display a significant decrease bone density, TGF-β1, NO, and NOS level, and a significant increase bone weight, IL-6, TNF-α, and Ca 2+ level. These parameters in the ST rats were evidently improved as compared to the OVX group. ST effectively mitigated ovariectomy-induced osteoporosis in rats by affecting endogenous metabolite-related metabolic mechanism and showed the natural alternative with potential for the treatment of PMOP.

show abstract

Section: Discussionmentioning

confidence: 99%

High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways to Evaluating the Efficacy and Exploring Potential Mechanisms of Osthole Against Osteoporosis Based on UPLC/Q-TOF-MS Coupled With Multivariate Data Analysis

Zhou

Shen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Similar results could be observed using eosinophils, where some studies found LPCs to increase cell migration [ 96 ] and adhesion [ 97 ]. Others, using physiological LPC-albumin complexes, discovered the ability of saturated LPCs to inhibit the activation and migration of isolated human eosinophils in vitro and in vivo [ 98 ]. LPCs were also found to either potentiate mast cell activation and secretion [ 99 ] or to inhibit histamine release, serving as a endogenous membrane stabilizers [ 100 ].…”

Section: The Complex Role Of Lpc In Vascular Inflammationmentioning

confidence: 99%

An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System

Knuplez

Marsche

2020

IJMS

Self Cite

128

View full text Add to dashboard Cite

Lysophosphatidylcholines are a group of bioactive lipids heavily investigated in the context of inflammation and atherosclerosis development. While present in plasma during physiological conditions, their concentration can drastically increase in certain inflammatory states. Lysophosphatidylcholines are widely regarded as potent pro-inflammatory and deleterious mediators, but an increasing number of more recent studies show multiple beneficial properties under various pathological conditions. Many of the discrepancies in the published studies are due to the investigation of different species or mixtures of lysophatidylcholines and the use of supra-physiological concentrations in the absence of serum or other carrier proteins. Furthermore, interpretation of the results is complicated by the rapid metabolism of lysophosphatidylcholine (LPC) in cells and tissues to pro-inflammatory lysophosphatidic acid. Interestingly, most of the recent studies, in contrast to older studies, found lower LPC plasma levels associated with unfavorable disease outcomes. Being the most abundant lysophospholipid in plasma, it is of utmost importance to understand its physiological functions and shed light on the discordant literature connected to its research. LPCs should be recognized as important homeostatic mediators involved in all stages of vascular inflammation. In this review, we want to point out potential pro- and anti-inflammatory activities of lysophospholipids in the vascular system and highlight recent discoveries about the effect of lysophosphatidylcholines on immune cells at the endothelial vascular interface. We will also look at their potential clinical application as biomarkers.

show abstract

“…This becomes particularly clear when one considers the lipid metabolism: Uremic dyslipidemia is characterized by hypertriglyceridemia and low HDL-C levels, whereas patients with advanced CKD rarely have elevated low-density lipoprotein cholesterol (LDL-C) levels [4]. In the healthy general population, HDL particles have strong anti-inflammatory, antioxidant and antithrombotic properties mediated by apolipoproteins, enzymes, sphingosine-1-phosphate saturated lysophosphatidylcholines and other lipids carried by these lipoproteins [5][6][7][8][9][10]. Recent studies have provided strong evidence that advanced stages of CKD with systemic oxidative stress and inflammation significantly reduce these protective activities of HDL, and dysfunctional or even pro-atherogenic forms of HDL have been identified [11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

In the general population, the ability of high-density lipoproteins (HDLs) to promote cholesterol efflux is a predictor of cardiovascular events, independently of HDL cholesterol levels. Although patients with chronic kidney disease (CKD) have a high burden of cardiovascular morbidity and mortality, neither serum levels of HDL cholesterol, nor cholesterol efflux capacity associate with cardiovascular events. Important for the following discussion on the role of HDL in CKD is the notion that traditional atherosclerotic cardiovascular risk factors only partially account for this increased incidence of cardiovascular disease in CKD. As a potential explanation, across the spectrum of cardiovascular disease, the relative contribution of atherosclerotic cardiovascular disease becomes less important with advanced CKD. Impaired renal function directly affects the metabolism, composition and functionality of HDL particles. HDLs themselves are a heterogeneous population of particles with distinct sizes and protein composition, all of them affecting the functionality of HDL. Therefore, a more specific approach investigating the functional and compositional features of HDL subclasses might be a valuable strategy to decipher the potential link between HDL, cardiovascular disease and CKD. This review summarizes the current understanding of the relationship of HDL composition, metabolism and function to their cardio-protective properties in CKD, with a focus on CKD-induced changes in the HDL proteome and reverse cholesterol transport capacity. We also will highlight the gaps in the current knowledge regarding important aspects of HDL biology.

show abstract

Lysophosphatidylcholines inhibit human eosinophil activation and suppress eosinophil migration in vivo

Cited by 26 publications

References 67 publications

High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways to Evaluating the Efficacy and Exploring Potential Mechanisms of Osthole Against Osteoporosis Based on UPLC/Q-TOF-MS Coupled With Multivariate Data Analysis

High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways to Evaluating the Efficacy and Exploring Potential Mechanisms of Osthole Against Osteoporosis Based on UPLC/Q-TOF-MS Coupled With Multivariate Data Analysis

An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System

Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease

Contact Info

Product

Resources

About